Ummino

Ummino is a Durham, North Carolina-based health and biosciences firm dedicated to pioneering clinically grounded microbiome solutions. With over 20 years of microbiome research, led by Dr. Andrea Azcarate and Dr. Jose Bruno, Ummino is addressing the growing metabolic health market, particularly with the rise of metabolic syndrome and GLP-1 therapies.

We specialize in developing Hummino®, a vital prebiotic inspired by natural HMOs, designed to selectively nourish beneficial gut microbes and strengthen gut barrier integrity. Hummino® works by restoring the natural balance to our microbiome and enhancing gut barrier function, reducing intestinal permeability and supporting immune system health.

Built on a team of microbiologists, clinical scientists, and business experts, including Charles Dykes, Ummino is committed to transforming lives through better nutrition and unlocking the microbiome’s potential for human health and wellness. Our mission is to target the adult microbiome and address the onset of unhealthy aging from microbiome decline.

Ummino has achieved SELF GRAS status, paving the way for healthier aging, and continues to advance its prebiotic production with support from BTEC and other strategic partners.